ImageneBio Inc. Common Stock (IMA)
Stock · NASDAQ · Health Care
$4.02as of 10/16/2026
Price chart
Active signals
IMA Signal Track Record
How signals performed across all stocks →What IMA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | -6.4% | 39% | October 8, 2026 |
| Bollinger Band Breakdown | 22 | -6.8% | 36% | October 8, 2026 |
| Bollinger Band Breakout | 18 | +2.8% | 56% | December 30, 2025 |
| 200-Day Moving Average TouchActive now | 7 | -6.2% | 29% | July 25, 2025 |
| Any 20-session window (baseline) | -2.6% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMA
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Onco…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 18
- Website
- inmagenebio.com/
Fundamentals
- 1-day range
- $3.98$4.26
- Market cap
- $63.50M
- P/E (trailing)
- —
- P/E (forward)
- -0.94
- EPS (trailing)
- $-5.34
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 13.5K
How ImageneBio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
ImageneBio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMAImageneBio Inc. Common Stock$4.04▲ 0.25%Market cap $63.50MP/E —$3.9$9.1
- GNTAGenenta Science S.p.A. American Depositary Shares$0.675▲ 0.90%Market cap $63.16MP/E —$0.55$10
- SCLXScilex Holding Company Common Stock$2.83▲ 0.35%Market cap $58.93MP/E —$2.77$27
- ELOXEloxx Pharmaceuticals Inc. Common Stock$13.03▼ 4.89%Market cap $71.48MP/E —$0$23.4
- CSBRChampions Oncology Inc. Common Stock$4.7▼ 1.88%Market cap $72.11MP/E —$4.59$8.31
- INKTMiNK Therapeutics Inc. Common Stock$9.41▼ 5.33%Market cap $54.80MP/E —$8.48$16.93
- LONALeonaBio Inc. Common Stock$5.2▼ 1.70%Market cap $73.36MP/E —$2.21$14.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMA ImageneBio Inc. Common Stock | $63.50M | — | $4.04 | ▲ 0.25% | $3.9$9.1 |
| GNTA Genenta Science S.p.A. American Depositary Shares | $63.16M | — | $0.675 | ▲ 0.90% | $0.55$10 |
| SCLX Scilex Holding Company Common Stock | $58.93M | — | $2.83 | ▲ 0.35% | $2.77$27 |
| ELOX Eloxx Pharmaceuticals Inc. Common Stock | $71.48M | — | $13.03 | ▼ 4.89% | $0$23.4 |
| CSBR Champions Oncology Inc. Common Stock | $72.11M | — | $4.7 | ▼ 1.88% | $4.59$8.31 |
| INKT MiNK Therapeutics Inc. Common Stock | $54.80M | — | $9.41 | ▼ 5.33% | $8.48$16.93 |
| LONA LeonaBio Inc. Common Stock | $73.36M | — | $5.2 | ▼ 1.70% | $2.21$14.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Yanina Grant-Huerta · August 14, 2026 · Grant56.0K
- Kristin Yarema · August 14, 2026 · Grant254.8K
- Yanina Grant-Huerta · August 14, 2026 · Grant39.0K
- Yanina Grant-Huerta · August 14, 2026 · Grant65.0K
- Kristin Yarema · August 14, 2026 · Grant250.0K
- Kristin Yarema · August 14, 2026 · Grant137.2K
- Kristin Yarema · July 25, 2026 · J115.1K
- Kristin Yarema · July 25, 2026 · Option Exercise38.4K
- Robert B. Lally · July 17, 2026 · Sale1.5K @ $5.34
- Robert B. Lally · July 16, 2026 · Sale1.7K @ $5.5
- David P. Bonita · June 16, 2026 · Grant15.6K
- Jonathan Jian Wang · June 16, 2026 · Grant15.6K
- Otello Stampacchia · June 16, 2026 · Grant15.6K
- Joseph P. Slattery · June 16, 2026 · Grant15.6K
- David P. Bonita · April 14, 2026 · Buy384.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 5.33M
- Total value held
- $26.56M
- Institutional holders
- 35
- Unknown1.11M
- Unknown959.3K
- Unknown754.7K
- Unknown455.4K
- Unknown378.6K
- Unknown334.4K
- Unknown325.2K
- Unknown200.7K
- Unknown129.2K
- Unknown124.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule
ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.